Research programme: phosphotransferase inhibitors - IgnytaAlternative Names: RXDX-102; RXDX-103; RXDX-104
Latest Information Update: 29 Jun 2016
At a glance
- Originator Nerviano Medical Sciences
- Developer Ignyta
- Mechanism of Action CDC7 protein kinase inhibitors; Proto oncogene protein c ret inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer